Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Raloxifene

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Raloxifene. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-002476-39 Sponsor Protocol Number: RLX0121 Start Date*: 2021-07-29
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Prospective study to evaluate the effects of Raloxifene therapy on SARS-CoV-2 immunity after COVID-19 vaccination
    Medical condition: The study will be conducted in non-oncological female patients older than 50 years who have received the first dose of a COVID vaccination, or who have received the full vaccination within 8 weeks...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004989-14 Sponsor Protocol Number: Start Date*: 2007-01-12
    Sponsor Name:Christie Hospital NHS Trust
    Full Title: The Effect of Raloxifene on Serum IGF-I in Patients with Acromegaly on long-term Octeotide Treatment
    Medical condition: acromegaly
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003936-25 Sponsor Protocol Number: RLX0120 Start Date*: 2020-10-31
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID-19 patie...
    Medical condition: Adult paucisymptomatic COVID-19 patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-004483-11 Sponsor Protocol Number: 80-83600-98-40120 Start Date*: 2016-07-08
    Sponsor Name:University Medical Center Utrecht
    Full Title: Raloxifene Augmentation in Patients with a Schizophrenia spectrum Disorder to reduce symptoms and improve cognition
    Medical condition: schizophrenia, schizoaffective, schizophreniform disorder or psychosis not otherwhise specified (DSM-IV 295.*)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10039635 Schizophrenia schizoaffective LLT
    21.1 100000004873 10039648 Schizophreniform illness LLT
    20.0 100000004873 10039632 Schizophrenia NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023983-42 Sponsor Protocol Number: RAL-S-01 Start Date*: 2011-09-13
    Sponsor Name: The Stanley Medical Research Institute
    Full Title: A randomized trial administering Raloxifene vs. Placebo as add-on to antipsychotics in post menopausal patients with schizophrenia or schizoaffecive disorder
    Medical condition: schizophrenia or schizoaffecive disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002053-69 Sponsor Protocol Number: 3068A1-301-WW Start Date*: 2002-08-13
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: FRACTURE INCIDENCE REDUCTION AND SAFETY OF TSE-424 (BAZEDOXIFENE ACETATE) COMPARED TO PLACEBO AND RALOXIFENE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN
    Medical condition: Reduction of new vertebral fractures in osteoporotic postmenopausal women- Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-001987-22 Sponsor Protocol Number: H4Z-MC-GJAR Start Date*: 2006-09-28
    Sponsor Name:Lilly S.A.
    Full Title: “Comparación de la Eficacia y Seguridad de Arzoxifeno frente a Raloxifeno en mujeres posmenopáusicas con Osteoporosis” The Comparison of the Efficacy and Safety of Arzoxifene versus Raloxifene in ...
    Medical condition: Mujeres postmenopausicas con osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007404-28 Sponsor Protocol Number: HRT Start Date*: 2009-02-12
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: Role of Estrogens in osteoclastogenesis and immunomodulation of T cells.
    Medical condition: post-menopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000245-20 Sponsor Protocol Number: FSJD-RAL-2010 Start Date*: 2011-06-21
    Sponsor Name:FUNDACIÓ SANT JOAN DE DEU
    Full Title: ENSAYO CLÍNICO DOBLE CIEGO A SEIS MESES, CONTROLADO CON PLACEBO, DE LA EFICACIA DE RALOXIFENO COMO TRATAMIENTO ADYUVANTE DE LOS SÍNTOMAS NEGATIVOS DE LA ESQUIZOFRENIA, EN MUJERES POSTMENOPÁUSICAS ...
    Medical condition: SINTOMAS NEGATIVOS EN ESQUIZOFRENIA
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002326-39 Sponsor Protocol Number: 1-10-72-57-15 Start Date*: 2015-08-19
    Sponsor Name:Gynecology Department,Herning Hospital [...]
    1. Gynecology Department,Herning Hospital
    2. Medical Department, Kolding Hospital
    Full Title: The influence of fat intake, estrogen, age, and gender on postprandial lipds and glucose
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004872 10050903 Postmenopausal symptoms LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002958-29 Sponsor Protocol Number: TERIPARATIDE Start Date*: 2006-08-02
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
    Full Title: STUDY OF CIRCULATING OSTEOBLAST-LINEAGE CELLS IN RELATION WITH TERIPARATIDE THERAPY.
    Medical condition: post-menopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10031285 PT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017144-14 Sponsor Protocol Number: 0903908 Start Date*: 2010-03-15
    Sponsor Name:Centre Hospitalier de Toulouse
    Full Title: Effets du traitement hormonal substitutif et du raloxifène sur les cellules dendritiques plasmacytoïdes et les lymphocytes B chez les femmes ménopausées
    Medical condition: Menopause
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027308 Menopause LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004281-32 Sponsor Protocol Number: SJDSSM-2 Start Date*: 2004-12-21
    Sponsor Name:San Joan de Déu. Serveis de Salut Mental
    Full Title: “Double blind, placebo-controlled study of efficacy, safety and tolerance of raloxifene as an adjuvant treatment for negative symptoms of schizophrenia in postmenopausal women” Estudio doble ciego...
    Medical condition: Trastorno esquizofrénico
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005618-38 Sponsor Protocol Number: OPG/RANKL/RANK/1 Start Date*: 2007-11-21
    Sponsor Name:U.L.S.S. 9 DI TREVISO
    Full Title: The OPG/RANKL/RANK system: implication for osteoporosis and atherosclerosis development. Potential role of the treatment with Atorvastatin
    Medical condition: Osteoporosis in hypercholesterolemic patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010587-42 Sponsor Protocol Number: 20080099 Start Date*: 2009-09-17
    Sponsor Name:Amgen Inc
    Full Title: A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned from Weekly or Daily Alendronate Therapy.
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) GB (Completed) PT (Completed) DE (Completed) FR (Completed) AT (Completed) IT (Completed) IE (Completed) ES (Completed) GR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002162-21 Sponsor Protocol Number: JECF-VITD-2011-01 Start Date*: 2012-04-24
    Sponsor Name:José Esteban Castelao Fernández
    Full Title: A phase II randomized, prospective, multicenter, placebo-controlled clinical trial to evaluate the chemopreventive effect of vitamin D in women at high risk of breast cancer.
    Medical condition: Women at high risk of developing breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000842-30 Sponsor Protocol Number: IEO62 Start Date*: Information not available in EudraCT
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Caelyx¿ as Adjuvant Treatment in Early Stage Luminal B Breast Cancer: a feasibility Phase II Trial
    Medical condition: Operated breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000687-30 Sponsor Protocol Number: AROAPOC3-2001 Start Date*: 2021-10-04
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Severe Hypertriglyceridemia
    Medical condition: Severe Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000688-57 Sponsor Protocol Number: AROAPOC3-2002 Start Date*: 2021-11-10
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Double-blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Mixed Dyslipidemia
    Medical condition: Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010726-19 Sponsor Protocol Number: 20080562 Start Date*: 2009-08-20
    Sponsor Name:Amgen Inc
    Full Title: A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates.
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) IT (Completed) ES (Completed) EE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 04:33:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA